Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effectiveness and safety of paliperidone
extended release (ER) in symptomatic participants with schizophrenia (psychiatric disorder
with symptoms of emotional instability, detachment from reality, often with delusions and
hallucinations, and withdrawal into the self) who were receiving treatment with any oral
(having to do with the mouth) antipsychotic medication and who needed to be switched to
paliperidone ER from the current oral antipsychotic therapy due to insufficient efficacy or
due to side effects.